ChromaDex, Inc.
10005 Muirlands Boulevard
Suite G, First Floor
Irvine
California
92618
United States
Tel: 949-419-0288
Fax: 949-419-0294
Website: http://www.chromadex.com/
Email: custsvc@chromadex.com
247 articles about ChromaDex, Inc.
-
ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model
7/9/2020
Dr. Charles Brenner and a team of scientists from three US universities find that Niagen® decreases Coronavirus replication in animal cells
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
-
ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models
7/7/2020
Study on ChromaDex’s NR ingredient to be conducted at NIH-NIAID’s Rocky Mountain Labs, one of the few Biosafety Level 4 labs in the U.S.
-
New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage
6/30/2020
ChromaDex shares new preclinical and clinical findings revealing potential of Niagen® across a variety of health conditions, paving the way for further clinical research
-
ChromaDex Research & Development Facility Earns ISO/IEC 17025:2017 Accreditation
6/17/2020
ChromaDex quality control and R&D facility in Longmont, Colorado obtains ISO/IEC 17025:2017 Accreditation
-
ChromaDex to Present at June 2020 Lytham Partners Virtual Investor Growth Conference
6/16/2020
ChromaDex Corp. is scheduled to participate in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 2:00pm ET.
-
First-of-Its-Kind Human Tissue Study Finds Link Between NAD Decline and Alcohol-Related Liver Disease (ArLD)
6/3/2020
New research from Dr. Charles Brenner expands human conditions with disturbed NAD systems including alcohol-related liver disease and other liver diseases.
-
ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting
6/1/2020
ChromaDex Corp. announced it has organized a virtual symposium entitled “Nicotinamide Adenine Dinucleotide in Human Health and Disease: The State of the Science on Nutrition Interventions” tomorrow Tuesday, June 2, from 8:30 to 10:00 AM EDT at NUTRITION 2020 LIVE ONLINE, the annual meeting hosted by the American Society for Nutrition.
-
ChromaDex to Participate in Panel on Master Files for Dietary Supplements Hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN)
5/27/2020
ChromaDex joins industry leaders to discuss “What New Dietary Ingredient Master Files Mean for Innovation & Compliance”
-
ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition
5/21/2020
ChromaDex Corp. announced Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa and ChromaDex Chief Scientific Advisor, was named the 2020 recipient of the Mary Swartz Rose Senior Investigator Award from the American Society for Nutrition and its Foundation.
-
Ninth Published Human Trial on Niagen® Nicotinamide Riboside (NR) Shows Increase in NAD+ Levels, Additional Research Highlights Downfalls of Nicotinamide Mononucleotide (NMN)
5/6/2020
ChromaDex highlights additional clinical and preclinical research strengthening science and understanding behind Niagen®
-
ChromaDex to Report First Quarter 2020 Financial Results on Monday, May 11, 2020
5/1/2020
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Mon., May 11, 2020 at 4:30 p.m. ET to discuss its financial results for the first quarter ended Mar. 31, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor confere
-
ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Nicotinamide Riboside (NR)
4/20/2020
Preclinical research from Dr. Charles Brenner and a team of leading scientists from three US universities concludes that key steps in coronavirus infection and innate immunity involve a tug-of-war with cellular NAD
-
Elysium Health, Inc. Loses Appeal of Patent Challenge Decision, Upholding Validity of ChromaDex Intellectual Property
4/14/2020
Given recently announced court closures and other restrictions due to the COVID-19 pandemic, the company would like to take this opportunity to provide an update on the ongoing litigation with Elysium Health.
-
ChromaDex Corrects Statements Made by an Unaffiliated Third Party Regarding its Product and COVID-19
3/12/2020
ChromaDex Corp. seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed client, implying unsupported health claims about Tru Niagen and COVID-19.
-
CHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS
3/10/2020
ChromaDex Corp. (NASDAQ:CDXC) today reported fourth quarter 2019 financial results.
-
New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal Model
2/27/2020
Preclinical study demonstrates the effects of short-term nicotinamide riboside (NR) supplementation in preventing hearing loss in animal models
-
ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing WorldwideChromaDex launches new research tools for the CBD industry with line of reference standards
2/3/2020
ChromaDex Corp. announced the expansion of its industry-leading reference standards business with a new line of cannabinoid reference standards available to researchers across the globe.
-
ChromaDex Achieves New Regulatory Milestones in the European Union & Australia
1/15/2020
ChromaDex receives authorizations to sell its patented, NAD+ boosting nicotinamide riboside chloride in the European Union and in Australia with market exclusivity
-
First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension
1/6/2020
Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex’s novel form of vitamin B3